KEY POINTS TADIOS was determined to be safe and well tolerated Serum levels of IL-1RA changed significantly, a biomarker that has a correlation with severity.
/PRNewswire/ Helixmith, a gene therapy company based in Seoul, Korea and San Diego, CA, announced today the results of a Phase 3 study for the treatment of.
Helixmith Announces Poster Presentations at the 2021 American Academy of Pain Medicine Meeting
News provided by
Share this article
Share this article
LA JOLLA, Calif., April 23, 2021 /PRNewswire/ Helixmith, a gene therapy company, announced today that three abstracts have been accepted for poster presentations at the virtual 2021 American Academy of Pain Medicine Annual Meeting to be held April 23 – 25, 2021.
Details of the poster presentations are as follows:
Title: Gene Therapy for Diabetic Peripheral Neuropathy: A Phase 3 study of VM202, a plasmid DNA encoding human hepatocyte growth factor
Helixmith Announces Poster Presentations at the 2021 American Academy of Pain Medicine Meeting